News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bicycle Therapeutics Limited Signs License Agreement with EPFL and Adds SR One and SVLS to Seed Syndicate


4/29/2010 9:23:26 AM

CAMBRIDGE, England--(BUSINESS WIRE)--Bicycle Therapeutics Ltd, a new biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specificity and binding affinity, has signed a License agreement with the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland and has secured additional seed funding from SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES